01 — At a Glance
The Agrochemical Titan That’s Busy Demerging Itself Into Oblivion
- 52-Week High / Low₹812 / ₹580
- Q3 FY26 Revenue₹12,269 Cr
- Q3 FY26 EBITDA₹2,434 Cr
- Q3 FY26 PAT₹490 Cr
- Q3 FY26 EPS (₹)₹4.70
- Book Value₹378
- Price to Book1.66x
- Dividend Yield0.95%
- Debt / Equity0.94x
- Net Debt (Dec 2025)₹23,317 Cr
The Teaser: UPL just delivered Q3 FY26 revenue of ₹12,269 crore (+12% YoY) with EBITDA margin holding firm at ~20%. Operating PAT grew 45% YoY. But here’s the plot twist that’ll keep you up: they approved a composite scheme on Feb 20, 2026 to demerge the India crop protection business into a separate listed entity called “UPL Global” while UPL becomes the strategic parent. Listing expected in 12–15 months. Advanta seeds is already filing its IPO DRHP. Net debt stands at ₹23,317 crore, leveraged at 2.5x EBITDA — markedly higher than peers, but improving. The company’s restructuring three entities simultaneously like it’s assembling IKEA furniture at 2 AM.
02 — Introduction
The Pesticide Giant Playing 4D Chess With Its Own Organization
Meet UPL Limited — a ₹53,043-crore behemoth that sells crop protection chemicals, seeds, and specialty chemicals across 140+ countries. Incorporated in 1969, listed since 1988, and the 5th largest agrochemical company globally by revenue. They’re present in every continent, own 43 manufacturing plants, and hold 14,000+ product registrations. Think of them as the FedEx of pesticides — just with more debt and a flair for corporate drama.
Q3 FY26 delivered a strong quarter: ₹12,269 crore revenue (+12% YoY), EBITDA margin steady at 20%, and operating PAT growth of 45% after adjusting for prior-year one-off tax reversals. But the headline that’s stealing the show? On Feb 20, 2026, the Board approved a composite scheme to demerge its India crop protection business (UPL Sustainable Agri Solutions, or UPL SAS) and merge it with the global crop protection business (UPL Cayman) to create a pure-play listed entity called “UPL Global.” The appointed date for step one is April 1, 2026. Expected listing: June 2027. Expected shareholder confusion: immediate.
Meanwhile, Advanta (the seeds platform) filed its draft red herring prospectus on Jan 19, 2026 for an IPO via offer-for-sale, with UPL and co-investor KKR selling stakes. The company’s also managing U.S. tariff headwinds, LATAM credit stress, and a working capital cycle that expanded 9 days YoY due to peak season build. It’s like watching a juggler add flaming torches mid-performance.
The Feb 2026 Concall (Management’s Take): “Comfortable and confident in achieving FY26 guidance” of 4–8% revenue growth and 12–16% EBITDA growth. Translation: we’re still uncertain about Q4, but the first three quarters looked solid enough that we’re not lowering our bar.
03 — Business Model: WTF Do They Even Do?
They Make Pesticides. They Sell Seeds. They’re Restructuring Everything.
UPL operates across three distinct (soon to be more distinct) business verticals. The first is crop protection — insecticides, fungicides, herbicides, and biopesticides. Second: seeds and associated products via Advanta, the 8th largest seeds player globally. Third: specialty chemicals and industrial chemical intermediates.
Crop protection is the heavyweight champion, representing ~84% of consolidated revenues. It’s split into two sub-platforms post-reorganization: UPL Corp (global crop protection business, including Arysta LifeScience acquired in fiscal 2019) and UPL SAS (India crop protection business). Geographic mix is 67% from LATAM, Europe, North America; 12% from India; 21% rest of world. The company claims presence in 140+ countries and direct access to 90% of global food basket.
Seeds (Advanta) contributes ~11% of consolidated revenue and is the growth engine. They’re positioned in hybrid seeds, field corn, grain sorghum, canola. Strong YoY growth: +22% in Q3 FY26, +14% volume growth. Q3 EBITDA +22% YoY. Management plans to unlock value via IPO, tapping into the high multiples that agritech and seeds businesses command globally.
Specialty chemicals (SUPERFORM) is the third vertical, churning out industrial chemicals, agro-chemical intermediates, and emerging super-specialty products like cyanide derivatives. Revenue contribution is ~5–6%, but margins are attractive. Q3 saw a sequential improvement with specialty share increasing to 27% from 18% last year.
No. 1 PositionIndiaCrop Protection Market
Global Rank5thAgrochemical Company
Countries140+Market Presence
Manufacturing Plants43Across the Globe
The Restructuring Play (Feb 20, 2026 Announcement): UPL approved a three-step composite scheme. Step 1 (Apr 1, 2026): UPL SAS merges into UPL via slump sale reversal. Step 2 (post-approval): India crop protection demerges from UPL into “UPL Global” (a new entity housing both India and global crop protection). Step 3: UPL Cayman (global business) merges into UPL Global. Post-completion, UPL Corp holds ~65.7%, promoters ~5.8%, public/PE ~29%. Promoter stake in UPL itself drops to 33.09% from current 33.51%. The goal: simplify structure, list UPL Global separately, unlock value. Timeline: listing June 2027. Confusion level: expert.
💬 Here’s my question for you: Do you think demerging crop protection from a strategic parent helps or hinders the business? Or is this just financial engineering to unlock PE valuations?
04 — Financials Overview: Q3 FY26 Results
The Numbers That Sparked a Restructuring Celebration
Result type: Quarterly Results | Q3 FY26 EPS: ₹4.70 | Annualised EPS (Q3×4): ₹18.80 | 9M FY26 revenue growth: +8% YoY
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 12,269 | 10,907 | 12,019 | +12.5% | +2.1% |
| EBITDA | 2,434 | 2,163 | 2,205 | +12.5% | +10.4% |
| EBITDA Margin % | 20% | 20% | 18% | Flat | +200 bps |
| PAT (Operating) | 452 | 312 | 553 | +45% | -18.3% |
| EPS (₹) | 4.70 | 3.71 | 5.95 | +26.7% | -21.0% |
The Real Story Below the Headlines: Reported PAT was ₹490 crore YoY, but Q3 FY25 had a one-off tax reversal benefit (~₹100+ crore) that inflated the base. Operating PAT (adjusting for that quirk) grew 45% YoY. Revenue growth of +12.5% on a sequential YoY is solid. EBITDA margin is steady at 20%, suggesting the company is maintaining profitability despite pricing pressure in certain molecules (looking at you, Sperto in Brazil). Net finance cost came down materially from ₹704 crore (Q3 FY25) to ₹639 crore (Q3 FY26) thanks to a $250 million perpetual bond prepayment in March 2025, lower SOFR by 70 bps, and bank repricing from the ratings outlook upgrade. Annualised EPS is ₹18.80 (Q3×4), but note that full-year FY26 is expected to be lower due to the tougher prior-year comparable base in Q4.
05 — Valuation: Fair Value Range
What’s This Company Actually Worth When It’s Pieces?
Join 10,000+ investors who read this every week.
